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What’s already known about this topic? 2 
• The variation in sensitivity of oral biopsy sites for direct immunofluorescence (DIF) in 3 
the diagnosis of oral MMP and PV has not been studied in detail in large series of 4 
patients.  5 
• Biopsy can be challenging due to difficult access and fragility of the oral mucosa. The 6 
diagnostic biopsy technique is therefore critical. 7 
 8 
What does this study add? 9 
• We have shown that a normal buccal punch biopsy (NBPB) from uninvolved oral 10 
mucosa is as sensitive as a perilesional biopsy (PLB) for diagnosis of oral PV, and 11 
superior to serology and histology. 12 
• For multisite MMP, while the PLB has the highest sensitivity, the NBPB is almost 13 
equivalent for diagnosis and is more sensitive than serology and histology. 14 
 15 
What are the clinical implications of this work? 16 
• Oral punch biopsy technique on uninvolved buccal mucosa tissue is a simple and safe 17 
practical method for diagnosing oral PV and MMP. 18 
 19 
Abstract 20 
Introduction: Accepted ‘standard practice’ for the diagnosis of immunobullous disease (IBD) is 21 
a perilesional sample for direct immunofluorescence (DIF). Our aim was to compare diagnostic 22 
outcomes of a normal buccal punch biopsy (NBPB) with a perilesional biopsy (PLB) for mucous 23 
membrane pemphigoid (MMP) and pemphigus vulgaris (PV).  24 
Method:  A retrospective analysis of 251 DIF positive MMP and 77 DIF positive PV 25 
patients was undertaken. Parameters analysed included the intraoral sites of involvement, 26 
histopathological, DIF and indirect immunofluorescence (IIF) findings.  27 
Results:   For MMP, PLB was positive in 134/143 (93.7%) samples compared with 28 
129/144 (89.6%) NBPB. The diagnostic sensitivity for PLB and NBPB (81.3% (39/48) and 29 
77.1% (37/48), respectively, among 48 patients who underwent both techniques and was not 30 
statistically significant (p=0.62). In gingival-only MMP, PLB was positive in 63/69 (91.3%) and 31 
NBPB was positive in 63/75 (84.0%). Among multisite MMP, PLB was positive in 71/74 32 
(95.9%) and NBPB was positive in 66/69 (95.7%). In gingival-only MMP, biopsies from 33 
reflected alveolar mucosa in 17 consecutive patients were positive in 17/17 cases (100%). For 34 
PV, PLB was positive in 42/43 (97.7%) compared with 42/42 (100%) NBPB. Histopathology 35 
3 
 
was diagnostic in 93/134 (69.4%) MMP and 38/41 (92.7%) PV. IIF was positive in 126/197 1 
(63.9%) MMP and 68/74 (91.9%) PV patient sera.  2 
Conclusion:  In the largest series of combined oral DIF results in MMP and PV, we have shown 3 
that a NBPB is almost equivalent as a PLB for the diagnosis of PV and multisite MMP and is more 4 




Autoimmune bullous diseases (AIBD) represent a heterogeneous group, characterised by 9 
immunoreactivity to structural proteins that maintain cell-cell and cell-matrix adhesion in the 10 
skin and mucous membranes.1 Desmoglein 1 and 3 are considered the main target antigens in 11 
pemphigus vulgaris (PV). In mucous membrane pemphigoid (MMP), the main target antigens 12 
proposed include bullous pemphigoid antigen 2 (BPA2/ BP180), bullous pemphigoid antigen 1 13 
(BPAg1/ BP230), laminin 332, alpha6 beta4 (α6β4) integrin and less commonly, collagen VII.2,3,4 14 
The oral cavity is affected in 84–96% of mucous membrane pemphigoid cases.2,5,6 The gingiva is 15 
the most commonly affected site (80%)7, followed by the buccal mucosa and palate, and less 16 
commonly, the tongue and lips. A subgroup of patients present with desquamative gingivitis 17 
(DG) as the sole manifestation (64% of cases),8 whilst other patients present with involvement 18 
of parts of the oral mucosa without DG, and in a third group all of the oral mucosa may be 19 
affected.9 In MMP, blisters may be present on the gingiva or palate.  20 
In PV, the oral mucosa is the first site of involvement in the majority of cases and the disease 21 
may remain confined to the mucosal surfaces or extend to involve the skin.10,11,12 Any site within 22 
the oral mucosa may be involved, however, the buccal mucosa, labial mucosa, ventrolateral 23 
tongue, and soft palate, all non-keratinised and readily traumatised, are especially vulnerable. 24 
The typical findings in both disorders are ulceration or erosions that may be covered by a 25 
yellow-white fibrinous slough. Gingival lesions usually include severe desquamative gingivitis, 26 
in which bullae have ruptured, to leave peeling tissue with red erosions or deep ulcers on the 27 
attached gingiva13. DG is the presenting feature in 21% of PV cases.8 Blisters are much less 28 
commonly seen; however small haemorrhagic blisters are sometimes seen on the buccal 29 
mucosa. As the mouth is very trauma prone, more usually, erythema or ulcers are present. 30 
Imminent blistering or conversely mucosal healing are both associated with a white appearance 31 
of the tissue and this still reflects disease activity.   32 
The diagnosis of MMP and PV involving the oral cavity is based upon a combination of clinical, 33 
histopathological analysis and immunopathologic findings.11,14 Early diagnosis and treatment 34 
are essential to reduce complications.  Direct immunofluorescence (DIF) is particularly helpful 35 
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in distinguishing PV from the subepidermal blistering diseases, though circulating 1 
autoantibodies detected by indirect immunofluorescence (IIF) or enzyme-linked 2 
immunosorbent assay (ELISA) may act as a surrogate where a biopsy is unavailable.7,15,16,17,18 3 
The accepted ‘standard practice’ however for diagnosis of MMP and PV, is laboratory evidence 4 
of an antibody-mediated disease at the epithelial basement membrane zone for MMP and the 5 
surface of epidermal keratinocytes for PV. This is accomplished by either a perilesional punch 6 
biopsy or incisional biopsy for DIF.14,19,20,21,22,23 For lesions in the mouth, an oral punch biopsy 7 
offers a convenient and practical method of confirming oral diagnosis. A recent study concluded 8 
punch biopsy was more sensitive than scalpel biopsy for suspected autoimmune bullous 9 
disease.24  The buccal mucosa can be exposed by everting the cheek, placing the thumb at the 10 
commissure and reflecting the corner of the mouth, applying external pressure on the cheek 11 
with the index finger to present the buccal mucosa.25  12 
 13 
Previous studies have reported sensitivity rates of 70%-80% using DIF for MMP7,22,23,26 and 90-14 
100% for PV17,19,26,27,28,29 using either perilesional or a buccal punch biopsy technique (Table 1). 15 
Selection of the optimal site for biopsy is important as the diagnostic ability of DIF depends on 16 
the presence of intact epithelium along all or most of the specimen. This can only reliably be 17 
achieved by sampling normal-appearing mucosa, combined with careful surgical techniques and 18 
minimal handling of the tissue.29 Obtaining an intact gingival biopsy in cases presenting with 19 
desquamative gingivitis alone is often difficult because the mucosa is thin, often friable and 20 
difficult to process. Hence inadequate surgical technique, sub-optimal surgical site selection, or 21 
improper tissue handling may lead to the loss of the gingival epithelium.  22 
 23 
Indirect immunofluorescence (IIF) is helpful in confirming a suspected diagnosis as well as 24 
differentiating closely related subepidermal bullous diseases by identifying their binding 25 
pattern. Assay of serum antibody titres by IIF may also help guide prognostication and therapy. 26 
In MMP, IIF studies for IgG and /or IgA are positive in approximately 50-84% of cases.7,30,31,32 27 
Patients with high IgG titres are more likely to need systemic management, and virtually all 28 
those with both circulating IgG and IgA require systemic immunosuppressive therapy.11 In PV, 29 
almost all patients with active disease have detectable IgG autoantibodies and titres tend to 30 
correlate with disease activity.33,34 Because the detection of circulating autoantibody by IIF is 31 




The variation in sensitivity of oral biopsy sites for DIF in the diagnosis of oral MMP and PV has 1 
not been studied in detail in large series of patients. The aim of the study was to compare the 2 
diagnostic sensitivity of an uninvolved 4mm NBPB with a PLB for MMP and PV and to ultimately 3 
make recommendations for the optimal sites to sample. 4 
  5 
Methods 6 
All patients had been referred to either the Oral Medicine department or St John’s Institute of 7 
Dermatology, Guy’s and St Thomas’ Hospital, London. A retrospective analysis of 251 DIF 8 
positive MMP and 77 DIF positive PV patients was performed. All patients were positive on at 9 
least one biopsy sample. Patients were biopsied routinely for diagnostic purposes using either a 10 
perilesional site for DIF, an unaffected site for DIF or both and histopathology. The potential 11 
value of an unaffected site had been previously shown in a small study in our department (REC 12 
95/304) and based upon these results we had incorporated this additional biopsy site into our 13 
routine clinical practice.  14 
 15 
In this analysis and service review, we collated the data on both intraoral and extraoral sites of 16 
involvement, histopathological findings, DIF results from PLB and/or NBPB and IIF. Biopsy 17 
specimens for DIF microscopy were placed in Michel's transport medium and referred to the 18 
laboratory. Michel’s transport medium (pH 7.0–7.2), was used to ensure that any specimens not 19 
reaching the lab for up to 28 days could be safely stored. It is associated with remarkable 20 
preservation of all components of the basement membrane zone.37 Normal saline may be used 21 
as an alternative if the biopsy sample can be shipped to the laboratory within 24 hours.38  PLBs 22 
were defined as those taken within a radius of 1 cm of a clinical lesion, and NBPB as clinically 23 
normal uninvolved buccal mucosa (Figure 1). Individual sections were incubated with 24 
fluorescein isothiocyanate-labelled antibodies against immunoglobulin (Ig)G, IgA, IgM, 25 
complement 3, and fibrinogen, and examined using a fluorescence microscope as previously 26 
described39,40. Indirect IF was undertaken as previously described and used monkey oesophagus 27 
and human skin for detecting pemphigus autoantibodies.39 EDTA-split skin was used to 28 
distinguish between different subepidermal bullous diseases.39,41 Commercial enzyme-linked 29 
immunosorbent assays (ELISAs) for the detection of antibodies to desmoglein (Dsg) 1 (Dsg 30 
antibody values >30U/ml = positive), Dsg3 (antibody values >30U/ml = positive), BP180 NC16a 31 
(antibody values >20U/ml = positive) and BP230 (antibody values >10U/ml = positive) were 32 
utilised. No other domains of BP180 have been tested nor has reactivity with laminin 332 as 33 
these are not yet commercially available. All ELISA kits used were manufactured by Medical and 34 
Biological Laboratories (MBL) Co. Ltd, Nagoya, Japan.  The threshold values used for positivity 35 
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were 30 U/ml (DSG1 and 3), 20 U/ml (BP180) and 10 U/ml (BP230), derived from analysis of 1 
sera from a UK blood donor population. The BP180 ELISA kits used detect antibodies binding to 2 
a recombinant, purified full-length NC16A domain of BP180 only.  Although the soluble 3 
ectodomain of BP180 contains a significant portion of the NC16A domain, the additional 4 
pathogenic domains of BP180 in this fragment are not assessed by the MBL ELISA. The values 5 
for sensitivity were calculated with the standard formula: sensitivity = true-positives/(true-6 
positives + false-negatives). The diagnostic sensitivity and DIF positivity between PLB and 7 
NBPB were tested using proportions test. 8 
 9 
Results 10 
Mucous Membrane Pemphigoid 11 
A total of 251 DIF positive patients were identified among whom a total of 304 biopsy samples 12 
for immunofluorescence were analysed (Figure 2). One hundred and forty-three underwent 13 
PLB, 144 underwent NBPB, 48 underwent both PLB and NBPB and 17 underwent reflected 14 
alveolar mucosa biopsies. DIF was positive in 134/143 (93.7%) PLB samples and 129/144 15 
(89.6%) NBPB samples. Forty-eight patients had DIF performed on both PLB and NBPB. 16 
Sensitivity was similar in these samples (p=0.62); 81.3% (39/48) for PLB versus 77.1% (37/48) 17 
for NBPB. 18 
 19 
One hundred and thirty-three (53.0%) patients had gingival-only (desquamative gingivitis only) 20 
oral disease. Of these cases, PLB was positive in 63/69 (91.3%) and negative in 6 samples.  21 
NBPB was positive in 63/75 (84.0%) of cases and negative in 12. One hundred and eighteen 22 
(47.0%) patients had multisite oral disease (any site of the oral mucosa may be affected, with or 23 
without gingival involvement). Of these, PLB was positive in 71/74 (95.9%) and NBPB was 24 
positive in 66/69 (95.7%). In contrast to those with gingival-only disease where 6/69 (8.7%) 25 
PLB and 12/75 (16%) NBPB biopsies were negative, in multi-oral site MMP only 3/74 (4.1%) 26 
PLB samples and 3/69 (4.3%) NBPB of multisite oral disease cases were negative. On review of 27 
the 3 cases with multisite disease and DIF negative PLB, the tissue was either heavily inflamed 28 
(1 sample) or there was loss of epithelium (2 samples). In the patients with DIF negative NBPB 29 
and multisite oral disease, all three patients had predominantly gingival disease with palatal 30 
involvement, with no buccal mucosa affected. Latterly, we have undertaken perilesional 31 
reflected alveolar mucosa in consecutive gingival-only MMP and demonstrated positive DIF in 32 
all 17 cases (100%). In those who underwent NBPB in addition to perilesional adjacent 33 




Histopathology was available for 134 patients and was diagnostic in 93/134 (69.4%). Indirect 1 
IF was positive in 126/197 (63.9%) of cases. A dual circulating anti-basement membrane zone 2 
(anti-BMZ) antibody response with IgG and IgA was detected in 22.9% (28/122 cases). 3 
Antibodies to IgG were detected in 72/122 (59.0%) and to IgA in 18.0% (22/122). Anti-4 
basement membrane zone antibodies were detected to the following titres: 64.2% (77/122) had 5 
a titre of 1/10, 20.5% (25/122) a titre of 1/100, 11.5% (14/122) a titre of 1/200, 0.8% (1/122) 6 
a titre of 1;400, 2.5% (3/122) a titre of 1/800 and 1.64% (2/122) a titre of 1/1600. Circulating 7 
autoantibodies against BP180 alone using standard commercial ELISA kits (antibody values 8 
>20U/ml = positive) were detected in 12/58 patients (20.6%), circulating autoantibodies 9 
against BP230 (antibody values >10U/ml = positive) in 6/58 (10.3%) patients and circulating 10 
antibodies to both in 9/58 (15.5%). In those who underwent PLB, autoantibodies to BP180 11 
alone were detected in 0/16 (0%), to BP230 alone in 1/16 (6.2%) and to both in 3/16 (18.6%) 12 
Overall 25% patients had detectable circulating BP autoantibodies. In NBPB cases, 13 
autoantibodies against BP180 alone were detected in 8/27 (29.6%), against BP230 alone in 14 
3/27 (11.1%) and to both in 4/27 (14.8%). In this subgroup 15/27 (55.6%) patients had 15 
detectable circulating BP autoantibodies. Of the 48 patients undergoing both biopsy techniques, 16 
autoantibodies against BP180 were detected in 4/15 (26.7%), against BP230 in 2/15 (13.3%) 17 
and against both BP180 and 230 in 2/15 (13.3%). Here 8/15 (53.3%) patients had detectable 18 
BP autoantibodies. Our patients have not been tested so far for anti-laminin 332 autoantibodies. 19 
 20 
Pemphigus Vulgaris 21 
 22 
A total of 77 DIF positive PV patients were identified and a total of 85 samples were analysed. 23 
(Figure 3). DIF was positive in 42/43 (97.7%) PLB samples and in 42/42 (100%) NBPB samples 24 
and the difference was not statistically significant (p=0.32). Eight cases had DIF performed on 25 
both PLB and NBPB. PLB was positive in seven and negative in one. NBPB was positive in all 26 
cases. Histopathology was diagnostic in 38/41 (92.7%) patients. IIF was positive in 68/74 27 
(91.9%) of cases. Circulating autoantibodies (antibody values >30U/ml = positive) against 28 
desmoglein 3 alone were detected in 35/60 (58.3%), against desmoglein 1 alone in 1/60 29 
(1.7%), and circulating autoantibodies against both desmoglein 1 and 3 were detected in 19/60 30 





An accurate diagnosis of PV and MMP is necessary in order to plan appropriate treatment 1 
protocols and define patient prognosis. The gold standard for the diagnosis is DIF14,19-23, 2 
however controversy exists regarding the optimal oral biopsy site for DIF studies.  3 
 4 
In the largest reported series to date of combined oral DIF results in MMP and PV, we have 5 
shown that a NBPB from uninvolved oral mucosa is as sensitive as a PLB for the diagnosis of PV 6 
and multisite MMP. Among 251 MMP patients, DIF was positive in 133/141 (94.2%) PLB 7 
samples and 129/144 (89.6%) NBPB samples and the difference was not statistically significant 8 
(p=0.14). The sensitivity was similar in the 48 patients who had DIF samples from both sites 9 
(p=0.62); 81.3% (39/48) for PLB versus 77.1% (37/48)) for NBPB though marginally more 10 
sensitive in PLB.  Among 118 patients with multisite oral MMP, there was no difference in 11 
sensitivity between PLB positive in 71/74 (95.9%) and NBPB positive in 66/69 (95.7%). Among 12 
77 PV patients, there was minimal difference between PLB 42/43 (97.7%) vs NBPB 42/42 13 
(100%) patients. Thus for PV, either site was highly reliable. Therefore, in patients with PV or 14 
multisite MMP, these data suggest that autoantibodies bind in-vivo throughout much of the oral 15 
mucosa.  16 
 17 
The same may not be true for pure gingival MMP. There are technical issues to consider when 18 
the inflammation is localised to the gingiva. MMP may present with desquamative gingivitis 19 
where the gingivae are often friable, fiery red, painful, and eroded, seen primarily on the labial 20 
or buccal aspect.8,42,43,44 The attached gingiva is a band of keratinized mucosa that stretches from 21 
the neck of the tooth to the reflected alveolar mucosa and is tethered to the underlying 22 
periosteum and bone. Establishing a positive diagnosis from a gingival sample can be technically 23 
difficult and importantly, from a long term oral health perspective, will result in a periodontal 24 
defect leading to an area subsequently prone to plaque accumulation and periodontal disease.30 25 
The gingival tissue in active disease is also fragile and thin and easily detached from the 26 
underlying connective tissue, which leads to loss of epithelium and potentially false negative 27 
results.45 A number of studies in addition to our own, have demonstrated gingival biopsies to be 28 
an inferior biopsy site that is also prone to non-specific inflammatory changes in that area.21,26,29 29 
Our data have shown that gingival-only MMP accounted for  the negative results in 6/9 (66.7%) 30 
PLB and 12/15 (80%) NBPB.  Thus, DIF sensitivity was lower in both PLB (91.3% vs 95.9%) and 31 
NBPB (84.0% vs 95.7%) for gingival vs multisite patients, respectively.  If lesions are present at 32 
several oral mucosal sites including the gingiva, it is therefore preferable to avoid the gingiva. 33 
Based upon these data and the finding that a PLB from 17 consecutive patients of reflected 34 
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alveolar mucosa was positive on DIF in gingival-only patients, we advocate a biopsy from this 1 
site, being perilesional but avoids loss of the papilla and loss of epithelium (Figure 4).  2 
 3 
When DIF is unavailable, assay of serum antibody titres by IIF may be helpful for diagnosis, 4 
acting as a surrogate in some patients, it may also be helpful as a prognostic indicator.  In this 5 
study, IIF was positive in 91.9% of PV cases and 63.9% of MMP cases. The detection of 6 
circulating autoantibodies by IIF was inconsistent and titres were variable. We have shown that 7 
a NBPB was superior to IIF for both PV and MMP. In MMP, circulating autoantibodies against 8 
BP180 alone were detected in 12/58 patients (20.6%), against BP230 in 6/58 (10.3%) patients 9 
and circulating antibodies to both in 9/58 (15.5%). A dual circulating anti-basement membrane 10 
zone (anti-BMZ) antibody response with IgG and IgA was detected in 28/122 (22.9%), 11 
antibodies to IgG in 72/122 (59.0%) and to IgA in 22/122 (18.0%). Circulating autoantibodies 12 
against desmoglein 3 alone were detected in 35/60 (58.3%) PV patients and circulating 13 
autoantibodies against both desmoglein 1 and 3 were detected in 19/60 (31.7%) i.e. overall 14 
Dsg3 antibodies were detected in 90% patients. These findings are consistent with data 15 
published elsewhere.46,47,48 Once commercially available ELISAs are available for the C terminal 16 
domain of BP180 and laminin 332, it is possible that diagnostic sensitivity will be significantly 17 
enhanced for MMP. 18 
 19 
Light microscopic (histopathological) studies are not considered an absolute criterion for the 20 
diagnosis of MMP14 or PV18. In this study, oral histology was diagnostic in 92.7% of PV cases and 21 
69.4% of MMP cases where this investigation was undertaken. For MMP, histology of lesional 22 
tissue typically demonstrates subepithelial blisters with or without leukocyte infiltration. The 23 
characteristic findings in PV include intraepithelial cleavage with acantholysis primarily 24 
localised to the suprabasal region with retention of basal keratinocytes along the basement 25 
membrane zone, resulting in an appearance that resembles a "row of tombstones". Combining 26 
the data from this study, NBPB was superior to histopathological examination for both PV and 27 
MMP. Although histological analysis generally should be performed, especially where the 28 
diagnosis includes other pathology such as lichen planus, it is expected that DIF will remain a 29 
gold standard in diagnosing autoimmune bullous disease. 30 
 31 
A number of studies have investigated the sensitivity of DIF in oral PV and MMP biopsies (table 32 
1). Jordan et al49 proposed that all patients with active oral PV should have a positive DIF for IgG 33 
on the cell surface of epithelial cells. Several studies have reported the sensitivity of DIF for oral 34 
MMP to be less sensitive.21-23 DIF sensitivity was 92% in oral PV and 78% in oral pemphigoid in 35 
10 
 
a study by Helander and Rogers21 and 89% in oral PV and 68% in oral pemphigoid in a study by 1 
Rogers and van Hale.50 Some authors27 have proposed that when investigating skin autoimmune 2 
diseases, that biopsies from normal-appearing tissue 5-10mm away from clinically apparent 3 
skin lesions might yield the best DIF test results, avoiding loss of immunoreactants by the 4 
inflammatory process in lesional samples. Many studies have described immunoreactants 5 
potentially present in the entire affected oral mucosal surface26 and in the unaffected oral 6 
mucosa.2 Sano et al reported no significant difference in the DIF detection rate between oral 7 
biopsies taken perilesionally (66.1%) or distant from the clinical lesion (64.7%).26 However 8 
their sample size for immunobullous cases was relatively small (n=125). The reasons for the 9 
variability in DIF sensitivity rates are suggested to be poor biopsy site selection (a site too close 10 
to or too distant from lesions), technical difficulties in sampling, diagnostic laboratory technical 11 
and reporting skills poorly accessible mucosal sites or uneven distribution of immunoreactants 12 
in the mucosa.51 In the oral cavity, chronic inflammation is particularly common around the 13 
gingivae which may partially account for the lower sensitivity of biopsies from this site.  14 
 15 
Diagnostic delay is very common when PV or MMP are confined to the oral mucosa.52,53 It is 16 
important to emphasize the significance of obtaining a good biopsy specimen, as the diagnostic 17 
ability of DIF depends on the presence of attached epithelium along all or most of the specimen. 18 
A specimen in which the epithelium has completely separated from the connective tissue is non-19 
diagnostic for subepidermal IB diseases and is extremely unreliable for PV as well. This 20 
separation can usually be avoided by sampling normal-appearing or erythematous perilesional 21 
mucosa, with a gentle surgical technique and minimal handling of the tissue. This study 22 
provides evidence that the oral punch biopsy technique on uninvolved buccal mucosa tissue is a 23 
simple and safe practical method for diagnosing oral PV and MMP. The technique requires no 24 
additional instruments or special skills, is technically easy and has high diagnostic value. In 25 




In the largest reported series of combined oral DIF results in MMP and PV, we have shown that a 30 
NBPB from uninvolved oral mucosa is as sensitive as a PLB for diagnosis of oral PV, superior to 31 
serology and histopathology though both also have high sensitivities. For multisite MMP, while 32 
the PLB has the highest sensitivity, the NBPB is almost equivalent for diagnosis and is more 33 
sensitive than histology and IIF. For pure gingival MMP, neither a PLB from the attached gingiva 34 
nor NBPB are sensitive enough to be individually reliable. Combining the two increases 35 
11 
 
sensitivity however, two biopsies for DIF increases both morbidity and cost. Our data has shown 1 
that a biopsy from reflected alveolar mucosa adjacent to an area of active full thickness gingival 2 
inflammation provides 100% sensitivity. For specialists not fully trained in complex oral biopsy 3 
techniques, a NBPB appears to be a good alternative technique to a PLB for all but pure gingival 4 
IB disease. It is a simple, reliable, sensitive technique and can be used by a variety of clinicians 5 







Figure legends: 13 
 14 
Figure 1: Perilesional (black circle) and normal buccal punch (yellow circle) biopsy sites 15 
Figure 2: DIF results in MMP. DIF was positive in 134/143 (94%) PLB samples and 129/144 16 
(90%) NBPB samples. DIF was positive in 17 (100%) of perilesional reflected alveolar mucosa 17 
biopsies in gingival-only MMP. 18 
Figure 3: DIF results in PV. DIF was positive in 42/43 (97.7%) PLB samples and in 42/42 19 
(100%) NBPB samples and the difference was not statistically significant (p=0.32). 20 
Figure 4: In patients with lesions confined to the gingiva, a biopsy should be taken from 21 
adjacent normal reflected alveolar mucosa. 22 
 23 
 24 
Table 1: Data from previous studies: diagnosis, site of active disease, biopsy site and result. 25 
MMP= mucous membrane pemphigoid, PV= pemphigus vulgaris, OLP= oral lichen planus, LAD= 26 








Diagnosis Site of active disease Biopsy site (Skin/oral cavity) Results 
Gilvetti et al, 
2018 
66 125 OLP (24) 
MMP (20) 
PV (4) 






Oral: Perilesional Biopsies for DIF taken in 45/66. 




7  7 MMP Oral: 
6 gingival only,  
1 multi-site  
Oral: Non-lesional buccal 
mucosa 
 
DIF +ve 100% (7/7) 
IIF -ve 100% (7/7) 


















DIF +ve 95% (74/78) 
Endo et al, 
2014 
27 52 MMP (13) 
PV (8) 
OLP (6) 
Oral: gingival Oral: Perilesional MMP: DIF:  +ve (16/24) 
            Histo: +ve (10 /26) 
PV:      DIF:  +ve (8/24) 
             Histo: +ve (8 /26) 
OLP:    DIF:  +ve (0/24) 
             Histo: +ve (3 /26) 
Non-specific: Histo: 5/26 
13 
 
Suresh et al, 
2012 
  




Oral: Gingival Oral: Gingival  DIF +ve: 
OLP 44.3% (106/239)  
MMP 25.1% (60/239)  
Pemphigus 2.1% (5/239) 
LAD 0.8% (2/239) 
Other 5.4% (13/239)  
Non-diagnostic/ negative: 22% 
(53/239) 





125 129 OLP (52) 
Cicatricial pemphigoid 
(14) 
Bullous pemphigoid (5) 
PV (9) 
 
Oral mucosa:  
Not defined 
Oral:  
Perilesional (<1cm from lesion) 
Distant (>1cm from lesion) 
DIF Distant +ve 64.7% 
DIF PLB +ve 66.1% 
 
DIF +ve: 
OLP 65.8% (52/79) 
Cicatricial pemphigoid 66.7% (14/21) 
Bullous pemphigoid 55.6% (5/9) 
PV 100% (9/9) 













Oral: 59 perilesional  
Skin: 24 perilesional 
Conjunctival: 43 perilesional or 
non-lesional 
DIF +ve overall 95.5% (64/67) 
IIF +ve 83.5% (56/67) 
Helander et al, 
1994 
500 500 Cicatricial pemphigoid 
(69) 
Bullous pemphigoid (2) 
MMP (10) 
PV (21) 
Oral Oral: Perilesional  PV: DIF +ve 89% (18/21) 
Pemphigoid: DIF +ve: 68% (55/81) 




Siegel at al, 
1993 







Cicatricial pemphigoid:  
DIF +ve 80% (4/5) 
 
LAD: DIF +ve (20% (1/5) 
Daniels et al, 
1981 




Lupus erythematous (6) 
MMP:  
Oral 32/33 








DIF +ve 97% (32/33) 
Histology 76% (25/33) 
 
PV 
DIF +ve 100% (10/10) 
Histology +ve 100% (10/10) 
Laskaris, 
1981 
58 58 PV (58) PV: Oral only Oral: Perilesional DIF +ve  98.3% (57/58) 
Histo: +ve 93.1% (54/58) 
Laskaris et al, 
1981 








Oral: Perilesional (33) 
Skin (33): Non-lesional 
Histo: Oral: 75.7% (25/33) 
 
DIF: +ve  
Oral: 96.9% (32/33) 
Skin: 3% (1/33) 
 
Siegel at al, 
1993 






DIF +ve 80% (4/5) 
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